Journal of Clinical Oncology
Articles in this Issue
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab in a low-grade serous ovarian cancer cohort: Trial in progress.
TPS5638 Background: Low grade serous ovarian cancer (LGSOC) typically has a poor response to chemotherapy, presenting an u...
Clinical pharmacokinetics and neutropenia-related pharmacodynamics of BAL0891 in patients with solid tumors.
e15161 Background: BAL0891 is a dual TTK and PLK1 inhibitor, and its pharmacokinetic (PK) and neutropenia-related pharmaco...
Efficacy and toxicity of the antitumor agent SPESN38-8.
e15528 Background: SN38 as TOP1 inhibitor is a potent anticancer agent; however, poor water solubility prohibited its dire...
Quality-adjusted survival comparison for tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with peritoneal metastasis (PM): Long-term follow-up from RATIONALE-305.
4034 Background: There is an unmet need for better treatment among patients (pts) with PM. A post hoc analysis of the phas...
Assessing loneliness in glioblastoma patients and caregivers using a nationwide survey.
12097 Background: Loneliness is associated with poorer health outcomes and quality of life in cancer patients, yet its pre...
Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).
TPS3681 Background: Encorafenib plus cetuximab is the standard of care for patients with BRAF...
Clinical and epidemiological profile and overall survival by age-adjusted Charlson Comorbidity Index in patients aged 80 years or older receiving cancer care in São Paulo, Brazil.
e13766 Background: In daily oncology practice, caring for people aged ≥ 80 years often means balancing tumor control with...
Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.
6564 Background: alloHCT provides curative potential for patients with AML. PTCy GVHD prophylaxis has changed this paradig...
A triage-aware neuro-symbolic approach for clinical trial matching in oncology: Real-world validation in lung and genitourinary cancer.
8536 Background: Low clinical trial accrual remains a critical barrier in oncology, driven by fragmented electronic health...
Phase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial.
TPS1164 Background: The use of immunotherapy beyond first-line setting is not yet routine in the treatment arsenal of pati...
Machine learning–based projections of cancer and depression mortality in the United States through 2035.
e22577 Background: Clinical depression is a relatively common yet frequently overlooked source of suffering among patients...
Safety and efficacy of atezolizumab with bevacizumab (A+B) for hepatocellular carcinoma (HCC) in patients with Child-Pugh (CP) class B cirrhosis.
e16219 Background: A+B is a first-line treatment with demonstrated safety and efficacy for patients with advanced HCC and...
A risk prediction model for severe, life-threatening, and fatal treatment-related toxicity.
12143 Background: Adverse events are major contributors to morbidity and mortality in patients receiving systemic cancer t...
Do the characteristics of the immune microenvironment of patients with 11q13 gene amplification reveal that it is an important factor for immune hyperprogression?
e16069 Background: Amplification of the 11q13 chromosomal region, encompassing genes such as CCND1 and FGF3/4/19, is frequ...
Chemotherapy use and survival by demographic and socioeconomic factors in primary central nervous system lymphoma: A population-based SEER analysis.
7057 Background: Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma confined to the brain and...
Ethno-religious inequities in clinical presentation and survivorship outcomes in breast cancer: A prospective cohort study.
e13633 Background: Breast cancer disparities related to ethnicity and religion are well described in U.S.-based population...
Evaluation of circulating tumor DNA (ctDNA) burden, detected mutations, and clinical outcomes in metastatic colorectal cancer (mCRC) using real-world data (RWD).
3659 Background: ctDNA is a promising prognostic biomarker in colorectal cancer; however, there is limited RWD on its prog...
Acute respiratory distress syndrome and non-metastatic solid tumor: A propensity score–matched analysis of the National Inpatient Sample database.
e14044 Background: Acute Respiratory Distress Syndrome (ARDS) remains a major cause of morbidity and mortality in hospital...
Metastatic male breast cancer: What do we know about treatment efficacy and survival? a multicenter retrospective study.
e13100 Background: Male breast cancer is a rare malignancy, representing less than 1% of all breast cancer cases worldwide...
Efficacy and safety of FOLFIRINOX versus gemcitabine-based regimens in locally advanced pancreatic carcinoma: A systematic review and meta-analysis.
e16391 Background: Locally advanced pancreatic cancer (LAPC) is often unresectable due to vascular involvement, and system...
Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin (AP) for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory phase II study.
6014 Background: Previously, neoadjuvant PD-1 plus AP followed by surgery and radiotherapy showed promising disease contro...
Phase I study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors.
2639 Background: LB1410 is a recombinant humanized anti-PD-1/TIM-3 bispecific antibody (BsAb) developed by L&L Bio Co....
Factors associated with clinical presentation and survival in early-onset triple-negative breast cancer: A real-world analysis.
e12751 Background: Early-onset triple-negative breast cancer (TNBC) is typically viewed as biologically aggressive, yet th...
A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study.
TPS2673 Background: The main challenge for developing CAR T therapies for solid tumors is the lack of targets that disting...
Association of social isolation with overall survival in cancer patients.
12011 Background: Social isolation has been associated with increased all-cause mortality, particularly in cardiovascular...